Literature DB >> 21690573

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.

Qiao Li1, Xiangming Lao, Qin Pan, Ning Ning, Ji Yet, Yingxin Xu, Shengping Li, Alfred E Chang.   

Abstract

PURPOSE: We investigated the antitumor reactivity of adoptively transferred effector B cells and the mechanisms by which they may mediate tumor regression in a spontaneous metastases model. EXPERIMENTAL
DESIGN: 4T1 breast cancer cells were inoculated into the flanks of syngeneic Balb/C mice to prime draining lymph nodes. Tumor-draining lymph nodes (TDLN) were harvested and B cells activated ex vivo with lipopolysaccharide and anti-CD40 monoclonal antibody. These activated B cells were adoptively transferred into mice inoculated with 4T1 tumor in the mammary fat pad. The induction of host T-cell immunity was evaluated.
RESULTS: Activated 4T1 TDLN B cells secreted immunoglobulin G (IgG) in response to tumor cells which was immunologically specific. These activated B cells were capable of mediating specific lysis of tumor cells in vitro. Transfer of these activated B cells alone mediated the inhibition of spontaneous metastases to the lung. Examination of the host revealed that the transfer of these B cells resulted in the induction of tumor-specific T-cell immunity as measured by cytotoxicity and cytokine (IFNγ and granulocyte-macrophage colony-stimulating factor) production. The combined transfer of activated T and B cells from TDLN resulted in tumor regression, which was greater than either cell population alone, with host B cells capable of producing IgG that mediated lysis of tumor in the presence of complement.
CONCLUSIONS: We have found that appropriately primed B cells can mediate tumor regression by itself and confers host T-cell antitumor immunity. Furthermore, effector B cells can serve as a useful adjunct in adoptive T-cell therapy. ©2011 AACR.

Entities:  

Mesh:

Year:  2011        PMID: 21690573      PMCID: PMC3149727          DOI: 10.1158/1078-0432.CCR-11-0207

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.

Authors:  Yeonseok Chung; Byung-Seok Kim; Yeon-Jeong Kim; Hyun-Jeong Ko; Sung-Youl Ko; Dong-Hyeon Kim; Chang-Yuil Kang
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

2.  Comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma".

Authors:  Masoud H Manjili; Maciej Kmieciak; Johanna Keeler
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

3.  Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism.

Authors:  Victoria Watt; Franca Ronchese; David Ritchie
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

4.  Inhibitory effects of B cells on antitumor immunity.

Authors:  Satoshi Inoue; Wolfgang W Leitner; Basil Golding; Dorothy Scott
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.

Authors:  Sangeeta Shah; Anagha A Divekar; Shannon P Hilchey; Hyun-Mi Cho; Corliss L Newman; Seung-Uon Shin; Hovav Nechustan; Pia M Challita-Eid; Benjamin M Segal; Kyung Hee Yi; Joseph D Rosenblatt
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

6.  Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.

Authors:  Qiao Li; Amelia C Grover; Elizabeth J Donald; Abbey Carr; Jiyun Yu; Joel Whitfield; Mark Nelson; Nobuhiro Takeshita; Alfred E Chang
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

7.  The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals.

Authors:  Koichi Yanaba; Jean-David Bouaziz; Takashi Matsushita; Takeshi Tsubata; Thomas F Tedder
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

8.  Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Authors:  Zuqiang Liu; Hae S Noh; Janet Chen; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

Authors:  Takekazu Iuchi; Seagal Teitz-Tennenbaum; Jianhua Huang; Bruce G Redman; Steven D Hughes; Mu Li; Guihua Jiang; Alfred E Chang; Qiao Li
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.

Authors:  Qiao Li; Takekazu Iuchi; Maria N Jure-Kunkel; Alfred E Chang
Journal:  Int J Biol Sci       Date:  2007-11-20       Impact factor: 6.580

View more
  57 in total

Review 1.  Double-edge Role of B Cells in Tumor Immunity: Potential Molecular Mechanism.

Authors:  Kai-Liang Zhao; Xiao-Jia Yang; Hong-Zhong Jin; Liang Zhao; Jian-Li Hu; Wen-Juan Qin
Journal:  Curr Med Sci       Date:  2019-10-14

Review 2.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

Review 3.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

4.  Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.

Authors:  Joshua Kellner; Caroline Wallace; Bei Liu; Zihai Li
Journal:  JCI Insight       Date:  2019-04-04

Review 5.  Toll-like receptors and B cells: functions and mechanisms.

Authors:  Claire M Buchta; Gail A Bishop
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity.

Authors:  Diana Rasoulouniriana; Nadine Santana-Magal; Amit Gutwillig; Leen Farhat-Younis; Yariv Wine; Corey Saperia; Lior Tal; Haim Gutman; Alexander Tsivian; Ronen Brenner; Eiman Abu Bandora; Nathan E Reticker-Flynn; Peleg Rider; Yaron Carmi
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 7.  B lymphocytes and cancer: a love-hate relationship.

Authors:  Grace J Yuen; Ezana Demissie; Shiv Pillai
Journal:  Trends Cancer       Date:  2016-12

Review 8.  The lymph node microenvironment and its role in the progression of metastatic cancer.

Authors:  Ethel R Pereira; Dennis Jones; Keehoon Jung; Timothy P Padera
Journal:  Semin Cell Dev Biol       Date:  2015-01-22       Impact factor: 7.727

9.  Hypoxia-inducible factors: a central link between inflammation and cancer.

Authors:  Daniel Triner; Yatrik M Shah
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

10.  Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma.

Authors:  Kim R M Blenman; Jake Wang; Shawn Cowper; Marcus Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2019-02-27       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.